Nicolas Garel: Combining psychoactive molecules and psychotherapy for patients suffering from mood and substance use disorders: a new therapeutic paradigm
Psychedelics June 14, 2024 DOI: 10.61373/pp024k.0016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Addiction |
| Key points | The profile presents Dr. Garel's research program as focused on integrating psychoactive molecules with psychotherapy as a potential treatment approach for patients with comorbid mood and alcohol or sedative use disorders, and notes his earlier Master's work on ketamine's potential role in discontinuing benzodiazepines and related drugs. |
Abstract
Dr Nicolas Garel is an Assistant Professor in the Department of Psychiatry and Addictology at the University of Montreal and a junior investigator at the Research Center of the Centre Hospitalier de l'Université de Montréal. Dr Garel did his psychiatry residency at McGill University before completing the Clinician-Investigator Program and a Master's degree at McGill University, studying the potential role of ketamine in the discontinuation of benzodiazepines and related drugs. Dr Garel then completed a clinical fellowship in Addiction Medicine at Stanford University. His research program focuses on the integration of psychoactive molecules in conjunction with psychotherapy as a unique potential treatment approach for patients with comorbid mood and alcohol/sedative use disorders. In this “Innovators & Ideas” section, we are excited to feature Dr Garel in our latest Genomic Press Interview. We are thrilled he took the time to answer our questions and share his valuable insights with our readers.